These data suggested that PIK3IP1 is a key gene in the combination of Ven with DZNeP and also revealed that DZNeP enhances the expression of PIK3IP1 to sensitize AML cells to Ven treatment. The gene discussed is PIK3IP1; the disease is acute myeloid leukemia.